Table 2.
PSA outcomes and %ARNL according to AR-V7 and ARv567es expression
| AR-V7+n = 36 | AR-V7- n = 18 |
|
|---|---|---|
| PSA50 at C5D1, n (%) | 13 (36) | 11 (61) |
| p-value | 0.09 | |
| PSA50 at any time, n (%) | 21 (58) | 14 (78) |
| p-value | 0.23 | |
| n = 16 | n = 8 | |
| C1D1 %ARNL, mean (SD) | 62.5 (14.3) | 63. (14.6) |
| C1D8 %ARNL, mean (SD) | 62.2 (15.2) | 42.1 (11.1) |
| C1D8 – C1D1 %ARNL, mean (SD) | −0.4 (13.2) | −21.5 (22.1) |
| p-value | 0.0023 | |
| ARv567es+ n = 42 |
ARv567es- n = 12 |
|
| PSA50 at C5D1, n (%) | 16 (38) | 8 (67) |
| p-value vs Group 1 | 0.11 | |
| PSA50 at any time, n (%) | 24 (57) | 11 (92) |
| p-value | 0.04 | |
| n = 18 | n = 6 | |
| C1D1 %ARNL, mean (SD) | 63.7 (16.8) | 62.6 (13.6) |
| C1D8 %ARNL, mean (SD) | 56.3 (17.4) | 55.2 (17.0) |
| C1D8 – C1D1 %ARNL, mean (SD) | −7.4 (11.8) | −7.4 (21.3) |
| p-value | 0.9985 | |
AR, androgen receptor; ARNL, androgen receptor nuclear localization; C1D1, Cycle 1 Day 1; C1D8, Cycle 1 Day 8; C5D1, Cycle 5 Day 1; PSA50, 50% reduction from baseline in prostate-specific antigen; SD, standard deviation.